All In Biotech

Drug Trial Radar · NCT06796062

Psilocybin for Opioid Use Disorder (OUD)

A Phase 2 Trial of Psilocybin as an Adjunctive Treatment for OUD Patients Who Continue to Use Illicit Opioids Despite Adherence to Methadone Treatment

Last checked: Nov 19, 2026Latest source record: Jan 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 480 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

480

Planned (sponsor's estimate)

Start

Dec 17, 2025

Primary completion

Feb 2029

Study completion Feb 2029

Sponsor

Lead sponsor
NYU Langone HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute on Drug Abuse (NIDA)
First posted
Jan 28, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a double-blind, adaptive, 2-stage, multi-site, phase 2 randomized controlled clinical trial designed to evaluate effects of moderate and high dose psilocybin, relative to low-dose psilocybin control, in OUD patients who continue to use illicit opioids in spite of adherence to standard-of-care treatment with methadone. Up to 480 participations will be consented to yield 240 randomized participants. This study is part of the NIH HEAL Initiative (https://heal.nih.gov/). In Stage 1, subjects will be randomly assigned to one of three groups: psilocybin 30 mg (high dose), psilocybin 20 mg (medium dose), and psilocybin 1 mg (control condition). By the end of Stage 1, an interim statistical analysis will be performed. The study will proceed to Stage 2 if at least one of the active dosages of psilocybin demonstrates 1) acceptable safety, based on analysis of safety data from Stage 1; and 2) conditional power of at least 25%, based on effect size estimates for the primary opioid use outcome (weeks of biologically-verified abstinence during 24 weeks of follow-up). Using a priori decision rules, the interim analysis will determine which of the active treatment groups (30 mg, 20 mg, or both) will be retained in Stage 2 of the trial. Stage 2 will continue the study, using the same treatment and assessment protocols, but retaining only the active dosage or dosages with a high probability of demonstrating efficacy relative to the psilocybin 1 mg control condition. The primary aims are to 1) Evaluate safety and efficacy outcomes in Stage 1 subjects in order to optimize design of the Stage 2, 2) Determine whether treatment with a single high (30 mg) or medium (20 mg) dose of psilocybin improves OUD treatment outcomes, relative to psilocybin 1 mg (control condition), in patients who continue to use illicit opioids despite adherence to methadone treatment, 3) Evaluate the effects of high-dose psilocybin and medium dose psilocybin on self-reported OUD-related neuropsychopathology, and 4) Identify likely responders to psilocybin treatment by using machine learning to model post-treatment OUD outcomes, based on pretreatment characteristics including all relevant clinical data, evaluations, and questionnaires.

Conditions

  • Opioid Use Disorder

Interventions

  • PsilocybinDrug

    One capsule (1 mg, 20 mg, or 30 mg) administered once orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Stage 1: The number of weeks during the 24 week follow-up period with no illicit opioid useTime frame: Up to 24 weeks
  2. Stage 1: Number of adverse eventsTime frame: Up to 24 weeks
  3. Stage 1: Change in QTc during drug administration sessionTime frame: Up to 24 weeks
  4. Stage 2: The number of weeks during the 24 week follow-up period with no illicit opioid useTime frame: Up to 24 weeks
  5. Stage 2: Number of adverse eventsTime frame: Up to 24 weeks
  6. Stage 2: Change in QTc during drug administration sessionTime frame: Up to 24 weeks
  7. Stage 2: Total score on the Penn Craving Scale for OpioidsTime frame: Up to 24 weeks
  8. Stage 2: Score on the Negative Affect subscale of the Positive and Negative Affect ScaleTime frame: Up to 24 weeks
  9. Stage 2: Total score on the 20-item version of the Short Urgency, Premeditation, Perseverance, Sensation seeking, and Positive urgency (UPPS-P) Impulsive Behavior Scale (SUPPS-P)Time frame: Up to 24 weeks

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Duke City Recovery Toolbox

    Albuquerque, New Mexico · Recruiting

  • University of New Mexico

    Albuquerque, New Mexico · Recruiting

  • StartCare

    Brooklyn, New York · Recruiting

  • NYU Langone Health

    New York, New York · Recruiting

  • VIP Community Services, Inc

    The Bronx, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.